Goldman predicts setbacks for Genzyme

Goldman Sachs added Genzyme to its Americas conviction sell list, saying that manufacturing setbacks at one of its plants may impair long-term growth at the company, and a near-term shortage of its drug Cerezyme may be more severe than expected. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.